Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trialM. William Audeh, Andrew Tutt, Richard T. Penson et al.|The Lancet|2010Cited by 2.3k